AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes
A Pair Of ‘Wild Card’ Studies Pay Off
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
You may also be interested in...
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.
Recent applications for approval also include another DMD therapy, another hemophilia B gene therapy, and a new antibiotic.
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’